Cynata Therapeutics : 18.11.01.Cynata Outlook and Investor Presentation

Important Information

This presentation has been prepared by Cynata Therapeutics Limited. ("Cynata" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Agenda

1 2 3

4

5 6

Significant progress in 2018

Meaningful impact on patient's lives

• • Completed first in-human trial of CymerusTM MSCs, treating 15 patients with acute graft-versus-host disease who had failed all other approved treatment options and had a bleak outlook

  Improved health outcomes for patients facing extremely grim prognosis

• • Completed data collection for Phase 1 trial in GvHD

• • Formal study report being finalised

• • Outstanding efficacy results

• • No safety concerns

• • International media attention

  Phase II trial expected to start in 2019

  Selected next clinical trial candidate

  • • Critical Limb Ischaemia (CLI): major clinical challenge and unmet need

  • • Severely impaired blood flow in the arteries: typically legs

  • • Trial design, scope, cost and schedule being developed

    CLI Phase II trial expected to start in 2019

  Deepened relationship with Fujifilm

  • • Commenced planning for Phase II trial in GvHD with Fujifilm

  • • Conducted joint session with Japanese regulator (PMDA) and joint media briefings

  Advanced pre-clinical programme

• • Clear supporting data for efficacy of Cymerus MSCs in multiple indications

• • Broadened patent portfolio

• • Enables multiple commercial discussions

Secured cornerstone investment

• • Fidelity International acquired ~9.5m shares through a combination of on market buying and a share placement of $5,2m at $1.275

• • Cash balance of $10.9m at 30 Sept 18

Fujifilm's actions indicate their support

Multiple irons in the fire

Strong cash runway

5